Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?
Executive Summary
With GlaxoSmithKline and Human Genome Sciences agreeing to a merger July 16, the key question for the multinational pharma becomes what it will do to strengthen sales for Benlysta, a lupus drug launched in 2011 that has fallen short of bullish commercial expectations.
You may also be interested in...
GSK's Immunology Strategy Edges Closer To Delivering
GlaxoSmithKline is working to establish an immuno-inflammation portfolio and extend learnings to other therapy areas. Sirukumab could be GSK's first new product in I&I beyond Benlysta. Chief Immunology Officer Paul-Peter Tak outlined his strategy in an interview with Scrip.
Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III
After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.
Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III
After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.